Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Alger Weatherbie Specialized Growth Fund H. George Dai, Joshua D. Bennett | “Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for glaucoma, corneal disorders, and retinal diseases. Shares contributed positively after the company reported strong fiscal third-quarter results, as revenue growth accelerated to approximately 37% year-over-year, driven by momentum in iDose, its flagship glaucoma product. The company also disclosed U.S. Food & Drug Administration (FDA) approval of its next-generation corneal health product, Epioxa, and indicated initial pricing was set materially above expectations, which was viewed as an incremental growth driver alongside the iDose ramp. BSD Analysis: Glaukos pioneered micro-invasive glaucoma surgery, creating an entirely new treatment category. Adoption is driven by demographic trends, physician familiarity, and improving reimbursement dynamics. The company continues expanding its product portfolio beyond early-generation stents. Growth has been strong, but margins lag as R&D and commercialization investment remain heavy. Over time, scale and mix shift should drive operating leverage. Competition is rising, but Glaukos still owns category credibility. This is a medtech innovator transitioning from disruption to platform economics.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
